Non-genomic effects of PPARγ ligands: inhibition of GPVI-stimulated platelet activation

L. A. MORAES, M. SPYRIDON, W. J. KAISER, C. I. JONES, T. SAGE, R. E. L. ATHERTON and J. M. GIBBINS
Institute for Cardiovascular & Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK

To cite this article: Moraes LA, Spyridon M, Kaiser WJ, Jones CI, Sage T, Atherton REL, Gibbins JM. Non-genomic effects of PPARγ ligands: inhibition of GPVI-stimulated platelet activation. J Thromb Haemost 2010; 8: 577–87.

Summary. Background: Peroxisome proliferator-activated receptor-γ (PPARγ) is expressed in human platelets although in the absence of genomic regulation in these cells, its functions are unclear. Objective: In the present study, we aimed to demonstrate the ability of PPARγ ligands to modulate collagen-stimulated platelet function and suppress activation of the glycoprotein VI (GPVI) signaling pathway. Methods: Washed platelets were stimulated with PPARγ ligands in the presence and absence of PPARγ antagonist GW9662 and collagen-induced aggregation was measured using optical aggregometry. Calcium levels were measured by spectrofluorimetry in Fura-2AM-loaded platelets and tyrosine phosphorylation levels of receptor-proximal components of the GPVI signaling pathway were measured using immunoblot analysis. The role of PPARγ agonists in thrombus formation was assessed using an in vitro model of thrombus formation under arterial flow conditions. Results: PPARγ ligands inhibited collagen-stimulated platelet aggregation that was accompanied by a reduction in intracellular calcium mobilization and P-selectin exposure. PPARγ ligands inhibited thrombus formation under arterial flow conditions. The incorporation of GW9662 reversed the inhibitory actions of PPARγ agonists, implicating PPARγ in the effects observed. Furthermore, PPARγ ligands were found to inhibit tyrosine phosphorylation levels of multiple components of the GPVI signaling pathway. PPARγ was found to associate with Syk and LAT after platelet activation. This association was prevented by PPARγ agonists, indicating a potential mechanism for PPARγ function in collagen-stimulated platelet activation. Conclusions: PPARγ agonists inhibit the activation of collagen-stimulation of platelet function through modulation of early GPVI signalling.

Keywords: glycoprotein VI, nuclear receptor, platelets, signaling.

Introduction

Diabetes mellitus is a major risk factor for vascular diseases and is associated with atherosclerosis and thrombotic complications [1]. Platelets play an important role in hemostasis and thrombosis, and are becoming increasingly implicated in inflammation and host defense mechanisms contributing to the pathogenesis and progression of the vascular complications of diabetes mellitus [2,3]. When blood vessels become damaged this results in the local exposure, generation or release of factors such as collagen and thrombin that trigger the function of platelets, initiating the hemostatic process. Platelet activation is associated with signaling that results in shape change and spreading, secretion and the release of multiple prothrombotic factors, and through the binding of plasma fibrinogen and von Willebrand factor (VWF) to integrin αIIbβ3, this leads to the formation of a stable platelet thrombus [2,4,5].

Collagen binding to the platelet receptor glycoprotein VI (GPVI) results in clustering thereby triggering the tyrosine phosphorylation of the associated transmembrane protein, the Fc receptor γ-chain by the Src-family kinases Lyn and Fyn [6,7]. This results in the binding of the tyrosine kinase Syk, which becomes tyrosine phosphorylated and activated, leading to the tyrosine phosphorylation of the transmembrane adaptor protein linker for activation of T-cells (LAT). LAT forms a platform for the assembly of a signaling complex that includes phospholipase Cγ2 (PLCγ2) which in turn becomes tyrosine phosphorylated. Phosphoinositide 3-kinase (PI3-K) is also recruited and through the generation of phosphatidylinositol (3, 4, 5)-trisphosphate, influences the recruitment and activation of phospholipase Cγ2 (PLCγ2), which liberates the second messengers 1,2-diacylglycerol and inositol 1,4,5-trisphosphate. The formation of these molecules is responsible for the mobilization of calcium from intracellular stores and activation of isoforms of protein kinase C (PKC) leading to secretion and aggregation. PI3-K activity results in the regulation of protein kinase B (PKB), which is important for platelet function and thrombus formation [2,8,9].

The peroxisome proliferator-activated receptors (PPARs) consist of a family of three nuclear receptor isoforms (α, β/δ, and γ) that heterodimerize with the retinoic X receptor (RXR)
and then modulate transcription of target genes [10]. PPARs play important roles in the regulation of metabolic pathways, including lipid biosynthesis and glucose metabolism [10,11]. This and implicated roles in cell differentiation, proliferation and inflammation have led to the hypothesis that the actions of PPARs may be associated with the prevention of cardiovascular complications [10–12]. Although platelets lack a nucleus, we and others have reported that they express a number of transcription factors including the steroid/nuclear receptors such as PPARγ, PPARα, the glucocorticoid receptor (GR), oestrogen receptor (ER), retinoic X receptor (RXR) and NFKB [13–19]. While steroid/nuclear receptors are recognized for their role in gene regulation, increasing evidence supports non-genomic actions of these receptors [20,21]. These studies have demonstrated that steroid hormones can induce rapid non-genomic modulation of cell function, although mechanisms have not been established for the non-genomic actions of the majority of these receptors.

The synthetic and clinically used drug rosiglitazone and the endogenous prostaglandin 15-deoxy-Δ 12,14-prostaglandin J2 (15d-PGJ2) are ligands of PPARγ [10]. Rosiglitazone is a member of the thiazolidinedione (TZD) family used to treat type 2 diabetes mellitus that effectively lowers blood glucose levels although improving sensitivity to insulin [22,23]. Several clinical studies have demonstrated that the treatment of diabetic patients with thiazolidinediones exerts a cardioprotective effect, indicated by a reduction in the risk of myocardial infarction in diabetic patients with an acute coronary syndrome [24–26].

In the present study, we investigated the effects of PPARγ agonists, 15d-PGJ2 and rosiglitazone on collagen-stimulated platelet activation, signaling and on thrombus formation. We demonstrate that PPARγ ligands modulate the activity of the GPVI collagen receptor-stimulated signaling pathway resulting in reduced levels of platelet activation, aggregation and thrombus formation under arterial flow conditions.

**Materials and methods**

**Reagents**

15d-PGJ2, SQ29548 and GW-9662 were purchased from Biomol (Affinity Research Products, Exeter, UK). Rosiglitazone was from Cayman Chemical (Alexis Corporation, Nottingham, UK). Horm-Chemie collagen was from Nycomed (Munich, Germany) and collagen-related peptide (CRP) from Professor Richard Farndale (University of Cambridge, UK). Anti-Syk (N-19, LR), anti-PPARγ (E8), anti-LAT, anti-PLCe2 antibodies and protein A/G agarose were purchased from Santa Cruz Biotechnology (Autogen Bioclear UK). Anti-Akt/PKBα was purchased from Upstate Biotechnology (Dundee, Scotland). PE-Cy5 labeled anti-Cd62P(P-selectin) was obtained from BD Biosciences (Oxford, UK) and MRS2179, Fura-2 AM and dimethylsulfoxide (DMSO) were from Sigma (Poole, UK). All other reagents were from previously described sources [27,28]. PECAM-1 knockout mice were provided by Professor T. Mak (University of Toronto, ON, Canada). All protocols involving the use of animals were approved by University of Reading Ethical Review Panel and authorized by a Home Office licence.

**Human platelet aggregation assay**

Washed platelets were prepared from fresh blood obtained from aspirin-free donors by differential centrifugation and aggregation measured by optical aggregometry (Chrono-log Corp., Havertown, PA, USA) as described previously [29]. Informed consent from human subjects was obtained and procedures approved by the University of Reading Research Ethics Committee.

**Mouse platelet aggregation assay**

Platelets were isolated from mouse blood (PECAM-1-deficient mice on a C57/Bl6 genetic background and matched C57/Bl6 controls), by cardiac puncture after termination, washed, counted using a Z2 coulter counter (Beckman Coulter, Hialeah, FL, USA) and aggregation assays performed at a density of 4 × 10⁸ cells mL⁻¹ by optical aggregometry as described previously [30–32].

**Immunoprecipitation and immunoblotting**

For protein precipitation assays, platelets were suspended at 8 × 10⁸ cells mL⁻¹ in buffer containing 1 mmol l⁻¹ ethylene glycol tetraacetic acid (EGTA), 10 μmol L⁻¹ indomethacin and 2 U mL⁻¹ apyrase to prevent platelet aggregation, release of TXA₂ and the secondary effects of adenosine 5-diphosphate (ADP), respectively. Immunoprecipitation, sodium dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting onto polyvinyldifluoride membrane were performed using standard techniques [28,32,33]. Densitometry was performed using a Bio-Rad GS-710 calibrated densitometer and QUANTITY ONE® software (Bio-Rad, Hemel Hempstead, UK). Data were normalized for protein loading established through reprobing of each blot for the protein of interest.

**Measurement of [Ca²⁺], by spectrofluorimetry**

Mobilization of calcium from intracellular stores was measured in platelets pre-loaded with the fluorescent dye FURA-2AM as described previously [27,33]. Platelets (2 × 10⁸ cell mL⁻¹) were incubated with PPARγ agonist or vehicle [DMSO 0.1% (v/v)] for 3 min and then stimulated with collagen (1.0 μg mL⁻¹) in a luminescence spectrophotometer (LS-50B; Perkin Elmer, Beaconsfield, UK). The ratio of emission values (excitation:340/380 nm) was calculated and converted to calcium concentration using FLWinLAB software (Perkin Elmer).

**α-granule secretion**

To measure α-granule secretion, surface exposure of P-selectin was assessed in whole blood by flow cytometry as reported
previously [34]. In these assays the GPVI-selective agonist CRP was utilized to avoid technical issues encountered with collagen because of integrin ζ2β1-dependent adhesion to collagen fibrils.

**Thrombus formation in vitro**

Whole fresh citrated blood was incubated with the lipophilic dye 3,3’-dihexylocarbocyanine iodide (DIOC6) and perfused through collagen-coated (100 μg mL⁻¹) micro-capillaries at a shear rate of 1000 s⁻¹ in the presence of PPARγ agonists 15d-PGJ2, rosiglitazone or vehicle control. Thrombi were subsequently visualized using a Leica DMI82 inverted confocal microscopy (using N PLANL 20×0.4 objective lens with 0–2 mm correction) and thrombus volume calculated from Z series images captured using TCS SP2 software (Leica, UK), as previously reported [31,32].

**Statistical analysis**

Aggregation traces are representative of at least three separate experiments from different donors. Numerical data are presented as mean ± SEM and statistical significance analyzed using the t-test.

**Results**

**PPARγ agonists 15d-PGJ2 and rosiglitazone inhibit collagen-stimulated platelet aggregation**

To determine if the natural PPARγ agonist, 15d-PGJ2 and rosiglitazone modulate platelet activation by the primary platelet agonist collagen, platelets were incubated with increasing concentrations of 15d-PGJ2, rosiglitazone (1, 3, 10 and 20 μmol L⁻¹) or vehicle [DMSO 0.1% (v/v)] for 3, 15 or 20 min prior to stimulation with collagen (1 μg mL⁻¹) for 90 s.

Platelet aggregation in response to collagen was found to be inhibited in a concentration-dependent manner by each of the PPARγ agonists 15d-PGJ2 (Fig. 1Ai–ii) and rosiglitazone (Fig. 1Bi–ii). Aggregation assays performed for up to 5 min duration confirmed this effect to be inhibition rather than delay in aggregation (Fig. S1). The extent of inhibition was found to be dependent of the time of incubation with PPARγ agonists, suggesting that some differences in apparent potency may be as a result of the differential ability to cross the plasma membrane. Incubation for 15 min with 15d-PGJ2 (Fig. 1Ai) or 20 min with rosiglitazone (Fig. 1Bi) enabled complete inhibition of aggregation at a concentration of 10 μmol L⁻¹. The effect of 15d-PGJ2 (3 and 10 μmol L⁻¹) on platelet aggregation induced by a range of collagen concentrations (0.1, 0.5, 1, 5, 10 and 25 μg mL⁻¹) was also examined. Levels of inhibition became reduced significantly with increasing concentrations of collagen. Inhibition was, however, maintained at higher concentrations of collagen. Incubation with 15d-PGJ2 (10 μmol L⁻¹) for 15 min resulted in a significant inhibition of platelet aggregation in response to high concentrations of collagen (10–25 μg mL⁻¹) (Fig. 1C).

The platelet response to collagen is partially dependent on the release of secondary agonists, such as ADP and TxA2. Furthermore, PPARγ agonists have been previously reported to inhibit platelet aggregation induced by ADP [13]. To examine whether the inhibitory effects of PPARγ agonists on collagen-stimulated aggregation was because of their ability to inhibit the actions of TxA2 and ADP secreted after stimulation with collagen, the thromboxane receptor (TPα/TPβ) antagonist SQ29548 and apyrase were used. Figure 2Ai demonstrates the ability of apyrase to partially inhibit the level of collagen-(10.0 μg mL⁻¹) stimulated platelet aggregation. At this concentration of collagen a maximal level of inhibition was achieved by 5 U mL⁻¹ apyrase. In the presence of apyrase (5 U mL⁻¹), the PPARγ agonist 15d-PGJ2 increased the inhibition of platelet aggregation, suggesting that the effects of PPARγ agonists on collagen-stimulated aggregation may not be explained through inhibition of ADP signaling alone (Fig. 2Aii–iii). Similar data were obtained using the P2Y1 antagonist MRS2179 (Fig. S2). The TXA2 antagonist SQ29548 partially inhibited collagen-(2.5 μg mL⁻¹) stimulated platelet aggregation; a maximal level of inhibition was achieved by 10 nmol l⁻¹ SQ29548 (Fig. 2Bi). In the presence of 10 nmol l⁻¹ SQ29548, the PPARγ agonist 15d-PGJ2 enhanced inhibition of platelet aggregation, suggesting that the effects of PPARγ agonists on collagen-stimulated aggregation, may not be because of attenuation of TXA2 signaling alone (Fig. 2Bii–iii).

**15d-PGJ2 and rosiglitazone signal through PPARγ, on platelets**

To establish whether the effects of PPARγ ligands on platelets are mediated by the receptor (PPARγ), similar aggregation assays were carried out in the presence of the PPARγ antagonist GW9662. Washed human platelets were treated for 5 min with PPARγ antagonist GW9662 alone or followed incubation for 15 min with PPARγ ligands 15d-PGJ2 or rosiglitazone prior to stimulation for 90 s with collagen (1 μg mL⁻¹). The PPARγ antagonist GW9662 alone (1, 3 μmol L⁻¹) did not modulate the levels of collagen-stimulated aggregation (Fig. 3A). GW9662 (1 μmol L⁻¹) did, however, cause a significant suppression of the inhibition of collagen-stimulated platelet aggregation by 15d-PGJ2 and rosiglitazone (3 μmol L⁻¹) (Fig 3B). These data indicate that the effects of 15d-PGJ2 and rosiglitazone are mediated, at least in part, through binding to PPARγ in platelets.

**Rosiglitazone and 15d-PGJ2 inhibit thrombus formation under arterial flow conditions**

The effect of 15d-PGJ2 and rosiglitazone on thrombus formation in whole blood was examined under arterial flow conditions *in vitro*. Whole blood was perfused through microcapillary tubes coated internally with collagen at a shear (laminar flow) rate of 1000 s⁻¹ in the presence of rosiglitazone or 15d-PGJ2 (0.1, 1 and 20 μmol L⁻¹) or vehicle [DMSO 0.1% (v/v)]. Thrombus size was calculated from the mean thrombus volume of five randomly selected fields of view. Figure 4A
(i–iii) shows composite images from Z series captured and analyzed by confocal microscopy in the presence of vehicle control and rosiglitazone. Both PPARγ ligands, rosiglitazone and 15d-PGJ2 inhibited the thrombus formation significantly in a concentration-dependent manner, where 1 µmol L\(^{-1}\) rosiglitazone or 15d-PGJ2 were able to inhibit thrombus formation by 50.4 ± 14.7 % and 66.6 ± 2.7 % compared with the vehicle control (Fig. 4B). To measure thrombus formation along the whole capillary, lysis buffer was passed through each capillary and protein concentration measured as an indicator of thrombus size. This approach is important because, as a result of the fibrilar nature of the collagen used, coating of microslides may not be completely uniform. As this may influence data collected from selected fields, analysis of platelet recruitment along the entire capillary is quantitatively more reliable. Consistent with the thrombus volume data, PPARγ ligands resulted in reduced protein concentration compared with control (Fig. 4C), and no significant differences were noted between rosiglitazone and 15d-PGJ2 treatments. The inclusion of the PPARγ antagonist GW9662 (3 µmol L\(^{-1}\)) was able to reverse the inhibitory effect of the PPARγ ligand 15d-PGJ2 (3 µmol L\(^{-1}\)) on thrombus formation (Fig. 4D).

It is possible that PPARγ agonists may reduce thrombus stability, which may result in greater levels of embolization. To explore this, thrombi were formed under arterial flow conditions, and subsequently perfused, again at arterial shear rate, with buffer containing rosiglitazone (1, 20 µmol L\(^{-1}\)) or solvent control. Thrombus volume was subsequently measured by confocal microscopy. After perfusion, a concentration of 1 µmol L\(^{-1}\) rosiglitazone caused no effect on thrombus stability, although an approximate reduction of 10% in thrombus volume was observed at 20 µmol L\(^{-1}\) (Fig. 4E).

**PPARγ ligands inhibit P-selectin exposure and collagen-stimulated mobilization of calcium**

Whole citrated blood was pre-incubated with increasing concentrations of the PPARγ ligand rosiglitazone (1, 3, 10...
and 20 μmol L⁻¹ or vehicle [DMSO 0.1% (v/v)] for 3 min and then stimulated with GPVI-selective ligand CRP (1 μg mL⁻¹) for 3 min and α-granule secretion was assessed by surface exposure of P-selectin by flow cytometry (Fig. 5A). Rosiglitazone was found to inhibit P-selectin exposure. Stimulation of the collagen receptor GPVI leads to rapid intracellular mobilization of calcium [33,35]. We therefore examined the ability of PPARγ ligands to modulate intracellular mobilization of calcium, on stimulation with collagen. Experiments were performed in the presence of 2 mmol l⁻¹ EGTA to prevent extracellular calcium influx. Fura-2AM-loaded washed platelets were pre-incubated with increasing concentrations of rosiglitazone (1, 3, 10 and 20 μmol L⁻¹) or vehicle [DMSO 0.1% (v/v)] for 3 min and then stimulated with collagen (1 μg mL⁻¹). Rosiglitazone caused inhibition of collagen-stimulated peak calcium concentrations (Fig. 5B). It is interesting to note that some aspects of platelet function show different levels of inhibition by a given concentration of PPARγ agonist, which may also point towards mechanisms of action.

PPARγ ligands inhibit the tyrosine phosphorylation of components of the GPVI signaling pathway

To begin to explore the mechanism through which PPARγ ligands inhibit collagen receptor-mediated signaling the effect of these ligands on the tyrosine phosphorylation of a number of...
receptor-proximal components of the GPVI signaling pathway was examined. Platelets were stimulated in the presence of EGTA (1 mmol L$^{-1}$), apyrase (2 U mL$^{-1}$) and indomethacin (10 µmol L$^{-1}$) to prevent aggregation and ensure the study of primary signaling events. In collagen signaling studies, where non-aggregation conditions are necessary, collagen concentra-
tions required to observe signaling were increased (25 µg mL⁻¹) in order to observe tyrosine phosphorylation of components of the GPVI pathway, consistent with previous reports [32,33]. PPARγ ligand concentrations used were therefore also increased.

The effect of rosiglitazone on collagen-stimulated tyrosine phosphorylation of Syk, LAT and PLCγ2 was investigated. Treatment of platelets with rosiglitazone was without a marked effect on the levels of collagen-stimulated tyrosine phosphorylation of Syk (Fig. 6A), although a trend for low-level inhibition that did not reach significance was observed. In contrast, rosiglitazone was found to cause a marked and concentration-dependent reduction in the levels of tyrosine phosphorylation of LAT (Fig. 6B) and PLCγ2 (Fig. 6C). The treatment of platelets with the PPARγ ligand rosiglitazone was found to result in inhibition of PI3-K activity as the levels of serine phosphorylation of a downstream marker of PI3-K signaling, Akt/PKBα, were reduced (Fig. 6D).

**PPARγ interacts with Syk and LAT upon stimulation of the GPVI pathway**

As in the presence of PPARγ agonists tyrosine phosphorylation of Syk remained unaffected, while downstream LAT phosphorylation was inhibited significantly, it was hypothesized that PPARγ may interact with Syk and/or LAT. In order to test this, Syk and LAT were immuno-precipitated from platelets treated with rosiglitazone (10–100 µmol L⁻¹) for 15 min prior to their stimulation with collagen (25 µg mL⁻¹) and immunoblot analyses were conducted to detect PPARγ. PPARγ was found to interact with Syk and LAT when platelets were stimulated with collagen in the absence of PPARγ ligands.

---

**Fig. 6.** The peroxisome proliferator-activated receptor-γ (PPARγ) ligand rosiglitazone modulates glycoprotein VI (GPVI) signaling. Washed platelets were incubated with rosiglitazone or vehicle control for 3 min and then stimulated with collagen (25 µg mL⁻¹) for 90 s. Syk (A), LAT (B), PLCγ2 (C) and PKBα/AKT were immunoprecipitated and immunoblotted to detect phosphotyrosine residues. PKBα/AKT phosphorylation (Ser473) was measured using a phosphospecific antibody. Equivalent protein loading was verified by reprobing for Syk (A), LAT (B), PLCγ2 (C) and PKBα/AKT (D). Densitometry analyses were performed on replicate experiments using blood from four different donors, and data normalized for protein loading levels [mean ± SEM (n = 4), t-test * P ≤ 0.05, ** P ≤ 0.01 and *** P ≤ 0.001].

© 2009 International Society on Thrombosis and Haemostasis
In the presence of the PPAR_γ ligand rosiglitazone, this interaction with both Syk and LAT was inhibited. The inhibitory effect on the PPAR_γ-Syk interaction was prevented by the addition of the PPAR_γ antagonist GW9662 (3 μmol L\(^{-1}\)) (Fig. 7C), indicating that this effect is PPAR_γ activation dependent. GW9662 also prevented rosiglitazone-dependent inhibition of PPAR_γ-LAT interactions (data not shown).

The inhibitory effect of PPAR_γ ligands on platelet function is not PECAM-1 dependent

Platelet endothelial cell adhesion molecule-1 (PECAM-1), has been reported to negatively regulate platelet function and thrombus formation [28,30,36]. Type 2 diabetes mellitus has been shown to be associated with the cleavage of platelet PECAM-1. These changes were reverted in patients treated with rosiglitazone, leading Randriamboavonjy et al. [37] to suggest that rosiglitazone may contribute to a decrease in the development of vascular diseases associated with type 2 diabetes mellitus through actions on PECAM-1. In order to establish if the inhibitory effect of collagen-stimulated platelet function by acute exposure to PPAR_γ ligands in vitro was dependent on PECAM-1, the effect of rosiglitazone on platelet aggregation was examined using washed platelets from PECAM-1-deficient mice.

Consistent with previous reports [30,36], platelets derived from PECAM-1-deficient mice exhibit a mildly exaggerated GPVI-mediated aggregation response to collagen when compared with wild-type mouse platelets (controls Fig. 8A,B: reduced lag phase and faster initial kinetics). Collagen-stimulated platelet aggregation in wild-type and PECAM-1-deficient platelets was inhibited in the presence of PPAR_γ ligand rosiglitazone, when compared with the vehicle control (Fig. 8A-C). This indicates that the acute (i.e. non-genomic) inhibitory effects of rosiglitazone on platelet function are not dependent on the presence or function of PECAM-1.

Discussion

While platelets are anucleate cells, recent reports have demonstrated that nuclear receptors such as the glucocorticoid receptor [15], RXR [17] and PPAR isoforms_γ [13] and β/δ [14] are expressed in these cells. Indeed, these studies have demonstrated the ability of ligands for intracellular receptors to

Fig. 7. Peroxisome proliferator-activated receptor-γ (PPAR_γ) interacts with Syk and LAT upon platelet stimulation with collagen. Washed platelets were incubated with rosiglitazone or vehicle control for 15 min and then stimulated with collagen (25 μg mL\(^{-1}\)) for 90 s. Syk (A) and LAT (B) were immunoprecipitated from cell lysates and immunoblotted to detect PPAR_γ levels. Equivalent protein loading was verified by reprobing for Syk and LAT. Densitometry analyses were performed on replicate experiments using blood from four different donors, and data normalized for protein loading levels expressed as a percentage of change in Syk-PPAR_γ association (A) and LAT-PPAR_γ association (B). GW9662 (3 μmol L\(^{-1}\)) was incubated with platelets for 5 min prior rosiglitazone or vehicle control for 15 min and then stimulated with collagen (25 μg mL\(^{-1}\)) for 90 s (C). Blots are representative of three different experiments (n = 3) [mean ± SEM (n = 4), t-test **P ≤ 0.01 and ***P ≤ 0.001].

© 2009 International Society on Thrombosis and Haemostasis
Non-genomic effects of PPARγ ligands

regulate platelet function in a non-genomic fashion [13–19]. PPARγ can be activated by a number of ligands, including lipids and eicosanoids, such as 5,8,11,14-eicosatetraynoic acid and the prostanoids PGA1, PGA2, PGD2 and 15d-PGJ2, docosahexaenoic acid, linoleic acid and the synthetic anti-diabetic glitazones (e.g. rosiglitazone) [10,11].

PPARγ ligands have been reported to inhibit platelet aggregation in response to ADP that is accompanied by a reduction in markers of platelet activation such as P-selectin exposure, TXA2 synthesis and sCD40L release [13]. Recently, we demonstrated that RXR ligands inhibit platelet activation stimulated by ADP or the TXA2 mimic U46619 and have proposed this to be mediated through suppression of Gq signaling, resulting in inhibition of mobilization of calcium from intracellular stores [17]. Although this has yet to be explored, the ability of PPARγ to interact with RXR may suggest some overlapping modes of action.

In this study, we have demonstrated that PPARγ ligands inhibit collagen-stimulated platelet aggregation, α-granule secretion and calcium mobilization. In the presence of the PPARγ antagonist GW9662, inhibition of aggregation was reversed, suggesting that this effect is at least in part, modulated by PPARγ in platelets. Failure to completely reverse inhibition indicates potential additional, and as yet uncharacterized, PPARγ-independent modes of action of these ligands. Increased concentrations of rosiglitazone or 15d-PGJ2 were associated with more accentuated levels of shape change upon stimulation with collagen. This is likely to reflect lower levels of aggregation in this optical assay, as PPARγ agonists alone do not stimulate shape change. We cannot, however, rule out the possibility that PPARγ normally serves to inhibit shape change.

As PPARγ agonists were found to inhibit collagen-stimulated calcium mobilization, a range of signaling proteins upstream of calcium in the GPVI collagen activation pathway were examined. Rosiglitazone did not cause marked inhibition of collagen-stimulated tyrosine phosphorylation of the kinase Syk, suggesting that the activity of upstream Src-family kinases, such Fyn and Lyn, is not modulated by PPARγ ligands. This ligand was, however, found to reduce the levels of tyrosine phosphorylation of the transmembrane adapter protein LAT and thereby PLCγ2, which is consistent with the inhibition of calcium regulation and α-granule secretion.

The tyrosine phosphorylation of LAT results in the recruitment and activation of PI3-K, leading to the generation of 3'-phosphorylated inositol phospholipid second messengers. Rosiglitazone treatment resulted in diminished collagen-stimulated phosphorylation of Akt/PKBγ, suggesting that the inhibitory effect of the PPARγ stimulation also results in suppression of PI3-K signaling. In the present study, interactions of PPARγ with Syk and LAT highlight a potential novel GPVI-dependent mechanism for PPARγ action on platelet activation. PPARγ in its inactivated state interacts with Syk and LAT (and possibly other components of the LAT signalosome). These interactions correlate with phosphorylation of Syk and LAT leading to the activation of proteins downstream within the GPVI pathway. Upon ligation of PPARγ, interactions with Syk and LAT were prevented, which coincided with diminished signaling downstream resulting in a reduction in platelet activation. The addition of the antagonist GW9662 was able to prevent the inhibitory effect of PPARγ ligands on interactions between PPARγ with Syk and LAT. Taken together, this suggests that the inhibitory actions of PPARγ ligands may be mediated within the GPVI signaling pathway at the level of LAT or the LAT signalosome and that inhibition of platelets by PPARγ ligands is not because of toxic effects. Further work is required to establish whether PPARγ is recruited to a signaling protein complex with both Syk and LAT, or whether interaction with Syk and LAT occurs independently. Furthermore, whether PPARγ interactions contribute to positive signaling through the GPVI pathway remains to be established.

It has been suggested that PPARγ ligands reduce the development of atherosclerosis and myocardial ischemia–reperfusion injury through inhibition of platelet activation and intra-arterial thrombus formation in animal models [38]. In support of this notion, we have observed that PPARγ ligands rosiglitazone and 15d-PGJ2 inhibit thrombus formation in human whole blood on immobilized collagen under arterial flow conditions.
Furthermore, perfusion with a low concentration of rosiglitazone, which is likely achievable in plasma of patients taking rosiglitazone (1 μmol L⁻¹) [39], caused no effect on thrombus stability. Together this suggests that PPAR₇ ligands may offer beneficial clinical actions through inhibition of thrombus formation without embolization effects. Future studies using in vivo models of thrombosis will be required to explore this further.

Treatment with TZDs such as rosiglitazone has been reported to reduce the activity of circulating platelets in patients with coronary artery disease [40] and type 2 diabetes mellitus [41]. More recently, treatment of type 2 diabetes with rosiglitazone has been reported to cause decreases in μ-calpain activity, the restoration of platelet PECAM-1 levels and diminished platelet responsiveness to thrombin [37]. As PECAM-1 and PPAR₇ ligands are able to inhibit the function of platelets, and they possess similar abilities to modulate calcium mobilization in these cells, we sought to determine whether the acute, non-genomic actions of rosiglitazone may be dependent on PECAM-1 expression. Examination of PECAM-1-deficient mouse platelets revealed, however, that the inhibitory effect of collagen-stimulated platelet aggregation by PPAR₇ ligands is unaffected by the presence or absence of PECAM-1. The possibility still exists, however, that PPAR₇ and PECAM-1 share similarities in their modes of modulation of GPVI-stimulated signaling in platelets.

Clinical trials have demonstrated that the treatment of diabetic patients with TZDs exerts a cardioprotective effect as evidenced by a reduction in the risk of myocardial infarction in diabetic patients [24–26,40]. However, there are conflicting reports demonstrating that administration of PPAR₇ agonists may be associated with an increased incidence of congestive heart failure, myocardial infarct and death [42–44]. These latter studies were limited by a lack of access to original source data, and were insufficiently statistically powered. Better characterization of such patients is therefore needed to determine the effect of TZDs on overall cardiovascular outcome.

Our findings indicate that PPAR₇ ligands inhibit collagen-stimulated platelet function through modulation of signaling downstream of the collagen receptor GPVI.

Addendum

Leandro A. Moraes and Michael Spyridon contributed equally to this work.

Acknowledgements

The authors wish to thank Professor T. Mak (University of Toronto, ON, Canada), Professor P. Newman (Milwaukee, WI, USA) and Professor S. Watson (University of Birmingham, UK) for the PECAM-1 knockout mice.

Sources of funding

This study was supported by research grants from the British Heart Foundation (RG/05/007), Heart Research UK (RG2543/07/10) and Wellcome Trust (082338/Z/07/Z).

Disclosures of Conflict of Interests

The authors state that they have no conflict of interest.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Fig. S1. Stimulation of PPAR₇ results in diminished platelet aggregation. Washed human platelets were treated with increasing concentrations of PPAR₇ agonist 15d-PGJ₂, prior stimulation for 300 s with collagen (1.0 μg mL⁻¹) and aggregation measured at 37 °C under constant stirring conditions. Traces are representative of three separate experiments.

Fig. S2. Inhibition of collagen-stimulated aggregation by PPAR₇ ligands is not dependent on inhibition of ADP effects. Washed human platelets were treated for 15 min with (A) MRS2179 or (Ai-ii) 15d-PGJ₂ (5 μmol L⁻¹) plus MRS2179 (5 μmol L⁻¹) prior to stimulation for 90 s with collagen (1.0 μg mL⁻¹) and aggregation measured at 37 °C under constant stirring conditions. Traces are representative of three separate experiments.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

References

1 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA. 2002; 287: 2570–81.
2 Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 2004; 117: 3415–25.
3 Weyrich AS, Zimmerman GA. Platelets: signalling cells in the immune continuum. Trends Immunol 2004; 25: 489–95.
4 Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102: 449–61.
5 Nieuwenhuis HK, Akkerman JW, Houdijk WPM, Sixma JJ. Human-blood platelets showing no response to collagen fail to express surface glycoprotein-Ia. Nature 1985; 318: 470–2.
6 Gibbins JM, Asselin J, Farndale R, Barnes M, Law CL, Watson SP. Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets. J Biol Chem 1996; 271: 18095–9.
7 Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JGJ, Saito T, Tybulewicz VLJ, Watson SP. The Fc receptor γ-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997; 16: 2333–41.
8 Gibbins JM, Briddon S, Shutes A, van Vugt MJ, van de Winkel JGJ, Saito T, Watson SP. The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activator of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem 1998; 273: 34437–43.
9 Gross BS, Meldford SK, Watson SP. Evidence that phospholipase C-γ₂ interacts with SLP-76, Syk, Lyn, LAT and the Fc receptor γ-chain after stimulation of the collagen receptor glycoprotein VI in human platelets. Eur J Biochem 1999; 263: 612–23.
10 Moraes LA, Piqueras L, Bishop-bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 2005; 110: 371–85.
Non-genomic effects of PPARγ ligands

11 Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497–505.

12 O’Brien JJ, Ray DM, Spinelli SL, Blumberg N, Taubman MB, Francis CW, Wittlin SD, Phipps RP. The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoids and synthetic PPAR ligands. Prost Lipid Med 2007; 82: 68–76.

13 Akhiyev F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP. Human bone marrow megakaryocytes and platelets express PPARα and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004; 104: 1361–7.

14 Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark MJ, Bishop-Bailey D, Warner TD, Mitchell JA. Role of nuclear receptor signalling in platelets: anti-thrombotic effects of PPARγ. FASEB J 2006; 20: 326–8.

15 Moraes LA, Paul-Clark MJ, Rickman A, Flower RJ, Goulding NJ, Perretti M. Ligand-specific glucocorticoid receptor activation in human platelets. Blood 2005; 106: 4167–75.

16 Moro L, Reineri S, Pirandia D, Pietrapiana D, Lova P, Bertoni A, Graziani A, DelliPilip C, Canobbio I, Torti M, Sinigaglia F. Non-genomic effects of 17β-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptorβ and Src Kinase. Blood 2005; 105: 115–21.

17 Moraes LA, Swales KE, Wray JA, Damazo A, Gibbins JM, Warner TD. Bishop-Bailey D. Nongenomic signalling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood 2007; 109: 3741–4.

18 Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009; 29: 706–11.

19 Malaver E, Romaniuk MA, D’atri LP, Pozner RG, Negrotto S, Benadzon R, Schattner M. NF-κB inhibitors impair platelet activation responses. J Thromb Haemost 2009; 7: 1333–43.

20 Croxtall JD, van Hal PTW, Choudhury Q, Gilroy DW, Flower RJ. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol 2002; 135: 511–9.

21 Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M. Nongenomic steroid action: controversies, questions and answers. Physiol Rev 2003; 83: 965–1016.

22 Lehmann JM, Moore LB, Smith-Oliver TA, Willkinson WO, Wilson TM, Klewier SA. An antiadhesive thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma. J Biol Chem 1998; 273: 19953–6.

23 Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004; 43: 297–305.

24 McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Hochman JS, Klein WW, Weaver WD, Plister M, Corbulan R, Dellborg M, Granger CB, van de Werf F, Topol EJ, Califf RM and SYNTAX Investigators. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 2004; 147: 246–52.

25 Sauer WH, Cappola AR, Berlin JA, Kimmel SE. Insulin sensitizing mediated by PPARs. Blood 2005; 104: 1361–7.

26 Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmson L, Betteridge J, Birckland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, et al. Second-year prevalence of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macrovascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–89.

27 Cicmil M, Thomas JM, Sage T, Barry FA, Leduc M, Bon C, Gibbins JM. Collagen, convulxin and thrombin stimulate aggregation-independent tyrosine phosphorylation of CD31 in platelets. Evidence for the involvement of Src family kinases. J Biol Chem, 2000; 275: 27339–47.

28 Cicmil M, Thomas JM, Leduc M, Bon C, Gibbins JM. PECAM-1 signalling inhibits the activation of human platelets. Blood 2002; 99: 137–44.

29 Asselin J, Gibbins JM, Achison M, Lee YH, Morton LF, Farddale RW, Barnes MJ, Watson SP. A collagen-like peptide stimulates tyrosine phosphorylation of syk and phospholipase C-2 in platelets independent of the integrin αβ2ζ. Blood 1997; 89: 1235–42.

30 Falati S, Patil S, Cross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Weiler H, Cooley B, Newman DK, Newman PJ, Furie BC, Furie B, Gibbins JM. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 2006; 107: 535–41.

31 Jones S, Tucker KL, Sata T, Kaiser WJ, Barrett NE, Lowry PJ, Zimmer A, Hunt SP, Emerson M, Gibbins JM. Peripheral tachykinins and neurokinin receptor NK1 are required for platelet thrombus formation. Blood 2008; 111: 605–12.

32 Tucker KL, Sage T, Stevens JM, Jordan PA, Jones S, Barrett NE, St-Arnaud R, Frampton J, Deddar S, Gibbins JM. A dual role for integrin linked kinase in platelets: regulating integrin function and alpha-granule secretion. Blood 2008; 112: 4523–31.

33 Hubbard GP, Stevens JM, Cicmil M, Sage T, Jordan PA, Williams CM, Lovegrove JA, Gibbins JM. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signalling pathway. Thromb Haemost 2003; 1: 1079–88.

34 Jones CI, Garner SF, Angenent W, Bernard A, Berzani C, Burns P, Farddale RW, Hogwood J, Rankin A, Stephens C, Tom BD, Walton J, Dudbridge F, Oweählund WH, Goodall AH. Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus. Thromb Haemost 2007; 5: 1756–65.

35 Smith JB, Selak MA, Dangelmaier C, Daniel JL. Cytosolic calcium as a secondary messenger for collagen-induced platelet responses. Biochem J, 1992; 288(Pt3): 925–9.

36 Patil S, Newman DK, Newman PJ. Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen. Blood 2001; 97: 1727–32.

37 Randriambavonjy V, Pistrof F, Bolek B, Schwinzer RHG, Dixit M, Badenhop K, Cohen RA, Busse R, Fleming I. Platelet sarcoplasmic endoplasmic Ca2+ATPase and μ-Ca2+ are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation 2008; 117: 52–60.

38 Dayuan Li, Chen K, Sinha N, Zhang X, Wang Y, Sinha AK, Romeo F, Mehtu JL. The effects of PPAR ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 2005; 65: 907–12.

39 Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of Rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003; 43: 252–9.

40 Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 2006; 26: 168–81.

41 Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, Jackson SK, Evans LM. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus – an effect probably mediated by direct platelet PPARγ activation. Atherosclerosis 2008; 197: 718–24.

42 Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129–36.

43 Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634–43.

44 Nissen SE, Wolski K. Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71.